New offering is intended to give manufacturers increased confidence in their supply chain of critical raw material choices for small molecule drug synthesis
Merck has introduced Chemiflex, a novel programme to help process development scientists solve raw material quality, regulatory and procurement challenges that have plagued small molecule manufacturers.
The Chemiflex Critical Raw Materials scheme includes materials, documentation and contract manufacturing services that save time and prevent certain setbacks by ensuring that critical raw materials chosen for active pharmaceutical ingredient synthesis will be available in quantities and qualities suitable for cGMP manufacturing.
In the past, developers often encountered quality and supporting documentation challenges when sourcing critical materials for late-stage development and commercial manufacturing. Merck’s new offering is intended to give customers increased confidence in their supply chain of critical raw material choices for small molecule drug synthesis.
Raw materials are the subject of increasing regulatory scrutiny. Merck’s Chemiflex is a solution for the sourcing of high-quality, critical raw materials that meet increasing regulatory documentation and supply chain requirements for small molecule drug development and manufacturing.
Company representatives will be available to discuss this programme and other innovative technologies at Stand No. 9J10, CPhI Worldwide. The event takes place on 9-11 October, at IFEMA, Feria de Madrid, Spain.